http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113292605-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F15-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555 |
| filingDate | 2021-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113292605-B |
| titleOfInvention | A kind of ruthenium complex of Erianin and its preparation method and pharmaceutical use |
| abstract | The invention provides an Erianin ruthenium complex, a preparation method and pharmaceutical use thereof, and belongs to the field of pharmaceuticals. The structure of the ruthenium complex of Erianin is shown in formula I. The Erianin ruthenium complex provided by the invention can effectively inhibit the growth of various tumor cells including breast cancer cells, liver cancer cells, lung adenocarcinoma cells and esophageal cancer cells; The IC50 value of MB‑231 was as low as 3.20±0.06 μM, and the IC50 value of lung adenocarcinoma cell A549 was as low as 2.95±0.04 μM. The Erianin ruthenium complex provided by the invention can be used to prepare medicines for preventing and/or treating various tumors such as breast cancer, liver cancer, lung adenocarcinoma, esophageal cancer, etc., and has broad application prospects. |
| priorityDate | 2021-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 26.